ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / CTY
SPTX (48) HROW (53) JANX (37) MLTX (32) ⌘ Pro Terminal →

City Therapeutics Inc. (CTY) — RQD Stock Rating Cockpit

$20.88 +0.82% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $20.87

City Therapeutics Inc. (CTY) carries a Roarable Rating of D (Sell) with 50/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D • SELL / AVOID Cap $1.04B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on CTY Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is CTY stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, City Therapeutics Inc. (NASDAQ: CTY) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 50/100 at a spot price of $20.88 (+0.82% 1D, market cap $1.04B). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, CTY ranks #263 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does CTY compare to SPTX and HROW in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), CTY carries a Roarable D (50/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, SPTX (Seaport Therapeutics Inc.) holds a D grade (48/100 RQD, P/E N/A, ROIC —, cap $1.05B) and HROW (Harrow Inc.) posts a D+ grade (53/100 RQD, P/E N/A, ROIC 42.9%, cap $1.06B). Among the 5-stock peer group, CTY leads on earnings multiple (N/A) while HROW leads on capital efficiency (42.9% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for CTY?
▼

For City Therapeutics Inc. (CTY), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #263 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $20.87 (-0.04%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 0.7% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record: Scores of 50/100 (D) historically posted market-perform odds over rolling 90-day windows (-1.4% avg 90D alpha vs SPY • 49.3% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →
RQD QUANT TACHOMETERSELL / AVOID • D
025507510050
JEV AI Jury Split (Battleground)
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D · Rk D+
Cash (12)Whales (6)SEC (13)Macro (10)CEO (9)
Each axis scored 0–20
12M PRICE TARGET CONE-3.6% Base Target
$25 Bull$20 Base$16 Bear
📬 FREE CTY RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for CTY)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (50/100 Composite)
🔍 WHY CTY SCORES 50/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (26% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▲ #2 Bullish Driver: Cash Engine Quality+12/20 pts (24% of score)

SEC XBRL Trailing 12 Months: 0.7% FCF Margin ($29.2M FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning6/20 pts (-14 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-14 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
58
Grade C$21.46-3.2% Next Q
Q2 (-2Q)
55
Grade C$20.77+4.2% Next Q
Q3 (-1Q)
53
Grade C-$21.65-3.6% Next Q
Current
50
Grade D$20.88-1.4% Hist 90D α
Trajectory: C (58) → D (50)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a CTY Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While CTY currently carries a cautious 50/100 (D) rating due to Whale & Options Positioning (6/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($21.73) and Max Pain ($21.92) forces dealer call-delta covering toward $25.07.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $CTY• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “CTY Beats Next Quarter EPS Consensus (Upcoming Quarter) & Holds Above 200D SMA”
YES 50%NO 50%Trade / Inspect Odds →
RSI-14 MOMENTUMNEUTRAL RANGE
53.930 Oversold · 70 Hot
ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)
3.80>3.0 Fortress Safe
PIOTROSKI F-SCOREHIGH QUALITY (7–9)
7 / 99-Pt Accounting
52-WEEK LASER RANGE36% OF RANGE
L: $19$20.88H: $24
1. Money & Cash Health● MIXED
Are profits real cash in the bank?

Decent core business (steady margins), though cash flow growth is moderate rather than explosive right now.

Factor Grade: C-RQD 12 / 20
2. Big Money & Insiders● TRIMMING
Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: D-RQD 15 / 40
3. Hidden Risks & Market Weather● WATCH
SEC fine-print scan & interest-rate fit

No major SEC filing blowups, though current interest rates and Fed liquidity call for normal position sizing.

Factor Grade: D+RQD 23 / 40
MULTI-MODEL JEV QUANT JURY DELIBERATION

JEV AI Jury Split (Battleground) on CTY

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
NEUTRAL (60)

14.0% ROIC with 42.0% gross margin and 2.80% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
NEUTRAL (65)

Altman-Z 4.20 and Piotroski 7/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
BEARISH (42)

15/40 institutional & smart-money positioning score with 10/20 macro alignment.

Bull Case: Why Buyers Like CTY
  • ✓Established market leader in Health Care with deep daily trading liquidity.
Bear Case: What Could Go Wrong
  • !Company executives have done more routine share selling than personal cash buying lately.
  • !Sensitive to high interest rates and tighter Federal Reserve market liquidity.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring CTY)

  • ✓Walkthrough of CTY's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
CTY // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -6.79%
2026-11-02O $21.08H $22.65L $19.19C $20.88VOL 224.4K
SMA50: $21.14
$24.21$22.85$21.49$20.13$18.77$20.882026-10-162026-10-202026-10-232026-10-282026-11-02
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

CTY Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 CTY Butterfly Map → + Track CTY →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on CTY today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for CTY. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for CTY today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CTY)

Health Care Rank #263 of 1016 ⚔️ SPTX vs CTY Full Matrix →

1. Head-to-Head Health Care Peer Comparison (CTY vs. SPTX, HROW, JANX, MLTX)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, City Therapeutics Inc. (CTY) ranks #263 by composite RQD confidence (50/100, grade D) and #354 by equity capitalization ($1.04B). Within this direct 5-issuer industry benchmark cohort, CTY leads on earnings valuation at N/A trailing P/E, while HROW leads on capital efficiency and profitability with 42.9% ROIC and 75.1% gross margin. HROW currently holds the highest overall quantitative score in the immediate peer group at 53/100 (D+) compared with CTY at 50/100 (D).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
CTY ACTIVE
City Therapeutics Inc.
D 50/100 — — — +0.82% $1.04B Benchmark Subject
SPTX
Seaport Therapeutics Inc.
D 48/100 — — — +2.09% $1.05B /sptx-vs-cty →
HROW
Harrow Inc.
D+ 53/100 — 75.1% 42.9% -0.14% $1.06B /hrow-vs-cty →
JANX
Janux Therapeutics Inc.
D- 37/100 — — -13.8% -0.06% $1.07B /janx-vs-cty →
MLTX
MoonLake Immunotherapeutics (Class A)
E 32/100 — — -35.0% -2.63% $1.00B /mltx-vs-cty →

2. CTY Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics

TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOT

City Therapeutics Inc. (CTY) operates in Biotechnology: Pharmaceutical Preparations (Health Care) with an equity capitalization of $1.04B, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.

3. CTY Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is CTY stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, City Therapeutics Inc. (NASDAQ: CTY) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 50/100 at a spot price of $20.88 (+0.82% 1D, market cap $1.04B). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, CTY ranks #263 in composite RQD confidence.

How does CTY compare to SPTX and HROW in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), CTY carries a Roarable D (50/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, SPTX (Seaport Therapeutics Inc.) holds a D grade (48/100 RQD, P/E N/A, ROIC —, cap $1.05B) and HROW (Harrow Inc.) posts a D+ grade (53/100 RQD, P/E N/A, ROIC 42.9%, cap $1.06B). Among the 5-stock peer group, CTY leads on earnings multiple (N/A) while HROW leads on capital efficiency (42.9% ROIC).

What are the biggest fundamental strengths and SEC risk factors for CTY?

For City Therapeutics Inc. (CTY), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #263 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is CTY trading relative to its 50-day, 200-day, and 52-week technical levels?

CTY last traded at $20.88 (+0.82% on volume of 224,395 shares), positioning the stock -3.91% below its 50-day simple moving average ($21.73) and -0.57% below its 200-day simple moving average ($21.00). Across its 52-week range of $19.19 to $23.88, CTY sits at the 36.0% percentile with a 14-day RSI of 53.9 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($18.27 to $23.49).

Direct Sub-Reports: CTY RQD Cockpit CTY 12M Forecast CTY Earnings & Move CTY Dividends & DRIP CTY Insiders & 13F CTY Whale Options CTY Profit Sankey CTY News & Why
ROARABLE RATING BRIEF • RQD 50/100 (D) ✓ SEC XBRL & RQD VERIFIED

CTY — City Therapeutics Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2026-11-03

1. Roarable Rating Brief: What This Means to a Prospective Investor

City Therapeutics Inc. (CTY) earns a live Roarable RQD composite score of 50/100, corresponding to a D letter grade (Roarable Sell) at a spot price of $20.88 (+0.82% 1D, market capitalization $1.04B).

  • Fundamental Cash Engine (12/20): Anchored by return on invested capital (ROIC) of —, gross margin of —, operating margin of —, and free cash flow yield of —.
  • Whale 13F & Options Flow (6/20) + Insider Conviction (13/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (10/20) + Forensic Balance Sheet (9/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of N/A, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

City Therapeutics Inc. (CTY) is a NASDAQ-listed issuer in the Health Care sector, operating within the Biotechnology: Pharmaceutical Preparations industry. Per the news wire, the company develops RNAi-based gene-silencing drugs (per the Quartz and Seeking Alpha headlines).

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D • RQD 50/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 6/20. With Fundamental Cash Engine at 12/20 and Institutional Whale Flow at 6/20, sustained execution supports upside toward the upper end of the $19.19 – $23.88 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Upstream and downstream dependencies are — Sector correlation data is — beyond the sector classification of Health Care and industry of Biotechnology: Pharmaceutical Preparations.

  • Key Question #1: Can CTY sustain or expand its — operating margin and — ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Will free cash flow conversion (— FCF yield) strengthen balance-sheet liquidity (Altman Z-Score N/A) toward the $23.88 52-week high?
  • Key Question #3: How sensitive is CTY's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

CTY Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for City Therapeutics Inc. (CTY) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to CTY Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

CTY Bull vs. Bear Conversation Board — What's Your Call at $20.88?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON CTY 🐻 33% BEARISH CONVICTION
1. Pick Your Side on CTY:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
MA MacroHawk_NYC RQD DEBATE OPENER • Cross-Asset Macro Desk 🐂 BULLISH 🎯 Target: $26.94 (+29.0%)
📌 Pinned Debate

Bloomberg reports the stock jumped 24% after an upsized IPO, a catalyst rated GREEN in the news wire.

The street is overcomplicating City Therapeutics Inc. (CTY). Bloomberg reports the stock jumped 24% after an upsized IPO, a catalyst rated GREEN in the news wire.. With an RQD score of 50/100 (D) and Forensic Balance Sheet at 13/20, any positive earnings surprise or guidance raise forces underweight funds to chase above $22.55.

SectorRotator 🐂 BULL

@SkepticalCFA Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Biotechnology: Pharmaceutical Preparations. If gross margin (0.0%) holds, EPS grows into the multiple faster than bears think.

SK SkepticalCFA RQD DEBATE OPENER • Fundamental Contrarian 🐻 BEARISH 🎯 Target: $17.12 (-18.0%)
Spot @ $20.88

The fundamental cash engine scores 12/20 with ROIC and FCF yield both at 0%, and the insider pillar scores lowest at 9/20.

Sitting on the sidelines or leaning short CTY above $20.88. The fundamental cash engine scores 12/20 with ROIC and FCF yield both at 0%, and the insider pillar scores lowest at 9/20.. Until Fundamental Cash Engine (12/20) and FCF yield (0.0%) inflect higher, upside is capped near $23.88.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%